WEF-001 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called WEF-001, a potential drug for people with certain types of advanced cancer that have a specific mutation known as KRAS. The researchers aim to assess the safety and effectiveness of WEF-001 when taken alone. Participants will receive one of several possible doses to determine the optimal one. Individuals with a KRAS-mutant solid tumor, such as advanced lung or colorectal cancer, whose disease has progressed after other treatments, may be suitable for this trial. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that WEF-001 is likely to be safe for humans?
Research has shown that WEF-001 is being tested for safety and effectiveness in people with advanced KRAS-mutant solid tumors. As the trial is in its early stages, detailed safety results are not yet available. Researchers are still learning about the treatment's tolerance and potential side effects.
Currently, the main goals are to understand how the body processes the drug and to observe any negative effects. As this is an early phase trial, complete safety information may not yet be available, introducing some uncertainty for participants. However, the research team closely monitors the treatment for safety.12345Why do researchers think this study treatment might be promising?
Unlike many standard cancer treatments that rely on chemotherapy or radiation, WEF-001 targets cancer cells with a novel approach. Researchers are excited because WEF-001 uses a unique mechanism of action that selectively attacks cancer cells while minimizing damage to healthy tissue. This targeted approach could potentially reduce side effects and improve overall effectiveness compared to traditional therapies.
What evidence suggests that WEF-001 might be an effective treatment for advanced KRAS-mutant solid tumors?
Research has shown that WEF-001 could be a promising treatment for advanced cancers with a KRAS mutation. These mutations often make cancer more aggressive and harder to treat. Early findings suggest that WEF-001 specifically targets these mutations, potentially slowing or stopping tumor growth. Although limited data from human studies exist, early research is exploring the effectiveness of this treatment against these challenging cancers. By focusing on the KRAS gene, WEF-001 aims to provide a new option for patients with limited treatment choices.12567
Are You a Good Fit for This Trial?
This trial is for individuals with advanced solid tumors that have a specific mutation called KRAS. It's open to those who haven't had success with other treatments and are in good enough health to participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Selection
Phase 1: WEF-001 will be administered to participating patients at 1 selected dose out of 7 possible doses.
Treatment
Phase 2: WEF-001 will be administered to participating patients at 1 selected dose out of 2 possible doses.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- WEF-001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Auricula Biosciences Inc.
Lead Sponsor
Simbec-Orion Group
Industry Sponsor